According to the official WeChat account of Zaiding Pharmaceuticals, on January 18th, Zaiding Pharmaceuticals partner Argenx announced that the Japanese Ministry of Health, Labour and Welfare has approved the subcutaneous injection form of VYVDURA® for the treatment of adult patients with systemic myasthenia gravis (gMG) who do not fully respond to steroid or non steroid immunosuppressants (ISTs) through subcutaneous injection. Based on this, Agamod has been approved in Japan for two administration methods: intravenous infusion and subcutaneous injection. In China, in July 2023, the application for the launch of a new drug for the treatment of systemic myasthenia gravis using the subcutaneous injection form of Agamod has been accepted by the National Medical Products Administration.